Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2026
Business Overview: Regeneron is a fully integrated biotechnology company inventing, developing, and commercializing medicines for serious diseases. Key products include EYLEA HD, EYLEA, Dupixent (collaboration with Sanofi), Libtayo, Praluent, and Evkeeza. The company operates in a single business segment.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $4,290.7 | $7,896.1 |
| Net Income | $1,296.9 | $2,024.1 |
| Diluted EPS | $12.23 | $18.95 |
| Operating Cash Flow | N/A | $1,891.9 |
| Cash & Cash Equivalents | $2,455.8 | $2,455.8 |
| Marketable Securities | $15,367.1 | $15,367.1 |
| Long-Term Debt | $1,986.6 | $1,986.6 |
| Working Capital | $12,915.4 | $12,915.4 |
Note: Marketable securities total includes current ($5,538.8M) and non-current ($9,828.3M) portions.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16.7% year-over-year (Q2 2026 vs. Q2 2025) and 17.8% for the six-month period. This was driven primarily by a significant increase in collaboration revenue from Sanofi.
- Net Income Decline: Despite revenue growth, net income decreased 6.8% in Q2 and 8.0% for the six months ended June 30, 2026, compared to the prior year. This was largely due to a decrease in "Other income (expense), net" (specifically unrealized gains on securities) and higher operating expenses.
- Product Sales Mix:
- EYLEA HD: U.S. net product sales increased 51.7% (Q2) and 52.1% (6M) due to higher volumes.
- EYLEA: U.S. net product sales decreased 45.4% (Q2) and 40.6% (6M) due to competitive pressures from biosimilars and patient transition to EYLEA HD.
- Libtayo: Global net product sales increased 30.0% (Q2) and 40.2% (6M).
- Collaboration Revenue: Sanofi collaboration revenue increased 49.9% (Q2) and 43.9% (6M), driven by higher Dupixent sales. Conversely, Bayer collaboration revenue decreased 33.4% (Q2) and 25.7% (6M) due to lower EYLEA sales outside the U.S.
- Operating Expenses: Research and development (R&D) expenses increased 14.8% (Q2) and 15.5% (6M). Acquired in-process R&D expenses surged to $127.0M in Q2 (from $10.0M prior year) due to upfront payments for new collaborations.
Guidance, Outlook, Risks, and Unusual Items
- Capital Allocation: The company repurchased $1.16 billion of common stock in Q2 2026. As of June 30, 2026, $2.534 billion remained available under share repurchase programs. A quarterly dividend of $0.94 per share was declared in Q2 and July 2026.
- Manufacturing Disruption: Gross margin on net product sales decreased (78% in Q2 vs. 83% prior year) due to unabsorbed manufacturing costs from a temporary interruption at the Limerick, Ireland facility in Q1 2026. Production has returned to normal levels.
- U.S. Government Agreements: In April 2026, Regeneron entered into agreements with the U.S. government to provide certain products to Medicaid at "Most-Favored-Nation Pricing" and to price future medicines similarly. In exchange, the company received exemptions from Section 232 tariffs through January 2029.
- Legal Proceedings:
- EYLEA Litigation: Ongoing patent infringement lawsuits against Amgen regarding biosimilars. The company recently won a motion to dismiss certain counterclaims in the 2025 lawsuit.
- Sanofi Litigation: Regeneron sued Sanofi alleging breach of the collaboration agreement regarding access to commercialization data for Dupixent.
- Government Investigations: Multiple civil complaints and investigations by the DOJ and state attorneys general regarding alleged violations of the Anti-Kickback Statute and False Claims Act related to patient assistance programs and pricing.
- Product Liability: Emerging lawsuits alleging Dupixent causes or exacerbates T-cell lymphoma.
- Risk Factors: Significant risks include biosimilar competition for EYLEA, reliance on Sanofi and Bayer for global commercialization, regulatory approval uncertainties for pipeline candidates (e.g., Fianlimab Phase 3 failure in melanoma), and potential impacts of tariffs and trade restrictions.
Investor Verification Checklist
- Biosimilar Impact: Verify the trajectory of EYLEA sales decline versus EYLEA HD growth to assess if the transition is sufficient to offset revenue loss from biosimilar competition.
- Sanofi Collaboration: Monitor the status of the litigation with Sanofi and its potential impact on the Dupixent profit-sharing arrangement, which represents a major revenue source.
- Manufacturing Capacity: Confirm that the Limerick facility disruption is fully resolved and assess any lingering inventory or cost impacts.
- Government Pricing Agreements: Evaluate the long-term financial impact of the "Most-Favored-Nation Pricing" agreement with the U.S. government on future margins.
- Pipeline Milestones: Track upcoming regulatory decisions for key candidates, including Garetosmab (FOP) in August 2026 and Cemdisiran (gMG) in November 2026.
- Legal Exposure: Assess the potential financial liability from ongoing DOJ investigations and product liability suits regarding Dupixent.